Reclassification to a Schedule III drug and possible Medicare coverage for pot could unlock new investment from pharmaceutical companies.
Recent Posts
- Spicejet shares fall 3%, IndiGo erases morning gains after DGCA mandates 60% free seat selection
- Iran-Israel war, pricey valuations drag metals, stocks plunge up to 15% since conflict began. Buy or sell 2025’s top sector?
- Godrej Properties acquires 20-acre land in Bengaluru, aims Rs 1,350 cr revenue from housing project
- Global Markets | Nikkei ends nearly 3% higher as AI, chip stocks rally
- Dhurandhar effect: PVR Inox shares jump 6% in three days; will Hamza’s revenge fire up earnings?